ClinicalTrials.gg
CompletedNCT01833754Updated Jul 22, 2022Results posted

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

A Phase 1 interventional study of Romosozumab in Osteoporosis, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Enrollment
18th of 20
24 · median 80
Started
2013
the only one that year
Phase 1
3 of 20
none open now
Registered
4th of 20
by date
Lead sponsor
8 of 20
Amgen

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 18th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1, and was the 4th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity profile of romosozumab after a single 210 mg subcutaneous dose in healthy participants and patients with stage 4 renal impairment (RI) or stage 5 RI requiring hemodialysis.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • Osteoporosis, Bone, Renal, Insufficiency, Kidney, Hemodialysis, Impairment
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

INCLUSION CRITERIA - ALL SUBJECTS :

  • Males or females ≥ 50 years of age
  • Body weight ≥ 45 and ≤ 110 kg
  • Willing to adhere to calcium and vitamin D supplementation requirements
  • Females must be of non-

INCLUSION CRITERIA - SUBJECTS WITH RENAL IMPAIRMENT (GROUPS 1 AND 2):

  • Group 1 - Stage 4 RI (estimated (eGFR) 15-29 mL/min/1.73 m²)
  • Group 2 - End stage renal disease requiring hemodialysis

INCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3):

  • Renal function defined as an estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m²

EXCLUSION CRITERIA - ALL SUBJECTS:

  • History of metabolic or bone disease (except for metabolic bone disease in renal impairment (RI) subjects)
  • History of osteoporosis, vertebral fracture, or fragility fracture of the wrist, humerus, hip, or pelvis after age 50
  • Recent bone fracture
  • Vitamin D insufficiency
  • Hypocalcemia or hypercalcemia
  • Hypomagnesemia
  • Hypophosphatemia
  • Untreated hyper- or hypothyroidism
  • Females with a positive pregnancy test
  • Males with pregnant partners
  • Females who are lactating/breastfeeding or plan to breastfeed on study and for 3 months after receiving the dose of study drug
  • History of spinal stenosis
  • History of facial nerve paralysis
  • Positive for (HIV) antibodies
  • Positive for surface antigen or detectable
  • (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical, or breast ductal carcinoma in situ) within 5 years before screening
  • History of solid organ or bone marrow transplants EXCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3)
  • Current hyper- or hypoparathyroidism
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1: Stage 4 Renal Impairment

    Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate \[eGFR\] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.

    Drug: Romosozumab

  • Experimental
    Group 2: ESRD Requiring Hemodialysis

    Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.

    Drug: Romosozumab

  • Experimental
    Group 3: Healthy Participants

    Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.

    Drug: Romosozumab

Interventions

  • Administered as three 70 mg/mL prefilled syringe injections

    Also known as: AMG 785, EVENITY™

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    A serious adverse event was defined as an adverse event (AE) that met at least 1 of the following serious criteria: * fatal * life-threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. A treatment-related adverse event (TRAE) was an AE assessed by the investigator as possibly related to the study drug, indicated by a "yes" response to the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?"

    Time frame: From the first dose of study drug up to day 85

  2. Number of Participants Who Developed Anti-Romosozumab Antibodies

    Two validated assays were used to detect the presence of anti-romosozumab antibodies. First, an electrochemiluminescent immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Second, a non-cell-based competitive binding bioassay was used to test positive binding antibody samples for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.

    Time frame: Baseline and day 85

  3. Albumin-Adjusted Serum Calcium Concentrations by Visit

    Albumin-adjusted calcium was derived as: Where serum albumin \< 40 g/L then albumin-adjusted calcium = measured total calcium (mmol/L) + 0.02 \* \[40 - serum albumin (g/L)\]; Where serum albumin ≥ 40 g/L then albumin-adjusted calcium = measured total calcium.

    Time frame: Baseline, days 8, 15, 22, 29, 43, 57, and 85/end of study visit

  4. Intact Parathyroid Hormone (iPTH)Concentrations by Visit

    Time frame: Baseline, days 8, 15, 22, 29, 43, 57, and 85/end of study visit

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Romosozumab

    Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85

  2. Time to Maximum Observed Serum Concentration (Tmax) of Romosozumab

    Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85

  3. Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)

    Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85

  4. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)

    Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85

07

Results

Posted Feb 25, 2019

Participant flow

This study was conducted at 5 centers in the United States. The first participant enrolled on 22 April 2013 and the last participant enrolled on 05 November 2013.

Participant flow — Overall Study
MilestoneGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Started888
Completed888
Not completed000

Outcome measures

PrimaryNumber of Participants With Adverse Events

A serious adverse event was defined as an adverse event (AE) that met at least 1 of the following serious criteria: * fatal * life-threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. A treatment-related adverse event (TRAE) was an AE assessed by the investigator as possibly related to the study drug, indicated by a "yes" response to the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?"

Time frame:
From the first dose of study drug up to day 85
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
All adverse events760
Serious adverse events110
AEs leading to discontinuation of study drug000
Fatal adverse events000
Treatment-related adverse events560
Treatment-related serious adverse events000
TRAEs leading to discontinuation of study drug000
Treatment-related fatal adverse events000
SecondaryMaximum Observed Serum Concentration (Cmax) of Romosozumab
Time frame:
Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Reported as:
Mean · µg/mL
Maximum Observed Serum Concentration (Cmax) of Romosozumab
µg/mLGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Maximum Observed Serum Concentration (Cmax) of Romosozumab28.9 ± 10.819.8 ± 7.322.4 ± 10.3
SecondaryTime to Maximum Observed Serum Concentration (Tmax) of Romosozumab
Time frame:
Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Reported as:
Median · days
Time to Maximum Observed Serum Concentration (Tmax) of Romosozumab
daysGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Time to Maximum Observed Serum Concentration (Tmax) of Romosozumab5.0 ± 10.85.0 ± 7.35.0 ± 10.3
SecondaryArea Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
Time frame:
Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Reported as:
Mean · days*µg/mL
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
days*µg/mLGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)637 ± 218444 ± 154443 ± 143
SecondaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
Time frame:
Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Reported as:
Mean · days*µg/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
days*µg/mLGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)642 ± 221447 ± 154445 ± 143
PrimaryNumber of Participants Who Developed Anti-Romosozumab Antibodies

Two validated assays were used to detect the presence of anti-romosozumab antibodies. First, an electrochemiluminescent immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Second, a non-cell-based competitive binding bioassay was used to test positive binding antibody samples for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.

Time frame:
Baseline and day 85
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-Romosozumab Antibodies
ParticipantsGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Binding antibody positive001
Neutralizing antibody positive000
PrimaryAlbumin-Adjusted Serum Calcium Concentrations by Visit

Albumin-adjusted calcium was derived as: Where serum albumin \< 40 g/L then albumin-adjusted calcium = measured total calcium (mmol/L) + 0.02 \* \[40 - serum albumin (g/L)\]; Where serum albumin ≥ 40 g/L then albumin-adjusted calcium = measured total calcium.

Time frame:
Baseline, days 8, 15, 22, 29, 43, 57, and 85/end of study visit
Reported as:
Mean · mmol/L
Albumin-Adjusted Serum Calcium Concentrations by Visit
mmol/LGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Baseline2.452 ± 0.2282.379 ± 0.1312.340 ± 0.057
Day 82.355 ± 0.1872.226 ± 0.2052.308 ± 0.072
Day 152.378 ± 0.1462.194 ± 0.1072.293 ± 0.070
Day 222.329 ± 0.1512.074 ± 0.1932.311 ± 0.104
Day 292.338 ± 0.1622.166 ± 0.2582.316 ± 0.062
Day 432.404 ± 0.2002.209 ± 0.1692.320 ± 0.065
Day 572.406 ± 0.1792.284 ± 0.1142.319 ± 0.070
End of Study2.428 ± 0.2012.291 ± 0.2642.330 ± 0.065
PrimaryIntact Parathyroid Hormone (iPTH)Concentrations by Visit
Time frame:
Baseline, days 8, 15, 22, 29, 43, 57, and 85/end of study visit
Reported as:
Mean · pmol/L
Intact Parathyroid Hormone (iPTH)Concentrations by Visit
pmol/LGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Baseline5.014 ± 1.59711.765 ± 12.0034.682 ± 3.432
Day 89.192 ± 3.07719.812 ± 16.2896.776 ± 3.612
Day 158.887 ± 4.74317.376 ± 10.1086.473 ± 3.880
Day 2210.425 ± 4.19029.724 ± 20.5656.818 ± 3.959
Day 2912.495 ± 5.24829.857 ± 20.4617.348 ± 3.997
Day 439.921 ± 5.90621.374 ± 14.1846.508 ± 3.289
Day 579.311 ± 4.57117.893 ± 11.1965.279 ± 2.215
End of Study6.958 ± 3.81223.503 ± 24.3394.457 ± 2.506

Adverse events

Collected over From the first dose of study drug up to day 85.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Stage 4 Renal Impairment—1/8 (12.5%)7/8 (87.5%)
Group 2: ESRD Requiring Hemodialysis—1/8 (12.5%)6/8 (75%)
Group 3: Healthy Participants—0/8 (0%)0/8 (0%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
AnaemiaBlood and lymphatic system disorders1/80/80/8
Mitral valve diseaseCardiac disorders0/81/80/8
Most frequent other events
Showing 10 of 28
Most frequent other events
EventGroup 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy Participants
Hyperparathyroidism secondaryEndocrine disorders4/80/80/8
HypocalcaemiaMetabolism and nutrition disorders1/84/80/8
ConstipationGastrointestinal disorders0/82/80/8
Atrial fibrillationCardiac disorders0/81/80/8
HyperparathyroidismEndocrine disorders1/80/80/8
Abdominal discomfortGastrointestinal disorders0/81/80/8
GastritisGastrointestinal disorders1/80/80/8
Gastrooesophageal reflux diseaseGastrointestinal disorders1/80/80/8
Gingival recessionGastrointestinal disorders1/80/80/8
HaemorrhoidsGastrointestinal disorders1/80/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy ParticipantsTotal
Mean66.5 ± 8.465.1 ± 6.763.0 ± 8.864.9 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy ParticipantsTotal
Female43714
Male45110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy ParticipantsTotal
Hispanic or Latino44210
Not Hispanic or Latino44614
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Stage 4 Renal ImpairmentGroup 2: ESRD Requiring HemodialysisGroup 3: Healthy ParticipantsTotal
American Indian or Alaska Native1001
Black or African American1315
White65718
08

Study locations

5 sites
  • Research Site
    Tempe, Arizona 85284, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Pembroke Pines, Florida 33028, United States
  • Research Site
    Orangeburg, South Carolina 29118, United States
09

References and documents

Publications

  • Hsu CP, Maddox J, Block G, Bartley Y, Yu Z. Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab. J Clin Pharmacol. 2022 Sep;62(9):1132-1141. doi: 10.1002/jcph.2050. Epub 2022 Apr 2. PubMed 35304747 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Feb 2014, 9 months.

Results were first posted in Feb 2019, 5 years after primary completion.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2013
First posted
Apr 17, 2013
StartActual
Apr 22, 2013
Primary completionActual
Feb 19, 2014
CompletionActual
Feb 19, 2014
Results first posted
Feb 25, 2019
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01833754
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 17, 2013
Start date
Apr 22, 2013
Primary completion
Feb 19, 2014
Completion
Feb 19, 2014
Results posted
Feb 25, 2019
Last update
Jul 22, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion